Zobrazeno 1 - 10
of 100
pro vyhledávání: '"P D. Delmas"'
Autor:
RENE RIZZOLI, NANSA BURLET, DAVID CAHALL, PIERRE D. DELMAS, ERIK F. ERIKSEN, DIETER FELSENBERG, JOHN GRBIC, MATS JONTELL, REGINA LANDESBERG, ANDREA LASLOP, PETER MATTON, SOCRATES PAPAPOULOS, ORHAN SEZER, MICHAEL SPRAFKA, JEAN-YVES REGINSTER
Publikováno v:
Остеопороз и остеопатии, Vol 10, Iss 2, Pp 19-21 (2007)
Externí odkaz:
https://doaj.org/article/d819336675f54f91859955db5079b64e
Publikováno v:
Остеопороз и остеопатии, Vol 11, Iss 1, Pp 32-32 (2008)
Externí odkaz:
https://doaj.org/article/3ae3c3ff6dca463cbafd36414d8cb6f0
Autor:
R. D. Chapurlat, P. D. Delmas
Publikováno v:
Osteoporosis International. 20:1299-1308
Microdamage accumulation due to fatigue loading may lead to fracture. In addition, several studies using animal models have suggested in recent years that bisphosphonates might increase microdamage accumulation. We have reviewed the literature after
Autor:
D O, Slosman, D M, Provvedini, P J, Meunier, P D, Delmas, J L, Sebert, M C, De Vernejoul, Y, Tsouderos, J Y, Reginster
Publikováno v:
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2(1)
Accurate cross-calibration (CC) and quality control (QC) programs for dual X-ray absorptiometry (DXA) instruments are necessary in order to guarantee appropriate measurements of bone mineral density (BMD) during longitudinal studies. This article det
Autor:
R Fisher, C Darte, F Singer, William R. Ryan, I Mizrahi, P D Miller, B C Kress, P D Delmas, K Panigrahi, O Reiss
Publikováno v:
Clinical Chemistry. 40:822-828
This two-site IRMA includes specific monoclonal antibodies for measuring skeletal alkaline phosphatase (B-ALP) in human serum. Assay calibration is based on mass units (micrograms per liter) and was established with purified B-ALP from a human osteos
Autor:
T, Thomas, J M, Feron, P D, Delmas, J, Kaufman, L, Tosi, S, Cummings, J, Lane, O, Johnell, M L, Bouxsein
Publikováno v:
Revue de chirurgie orthopedique et reparatrice de l'appareil moteur. 92(2)
Publikováno v:
Climacteric : the journal of the International Menopause Society. 8(2)
To compare the effects of a 12-week treatment with 17ss-estradiol given alone and in sequential combination with 3.75 mg of nomegestrol acetate (Naemis), or a placebo on biochemical markers of bone turnover in menopausal women.A double-blind, randomi
Autor:
R, Chapurlat, P D, Delmas
Publikováno v:
La Revue de medecine interne. 25
New intermittent regimens with bisphosphonates such as oral ibandronate, and maybe annual intra-venous zoledronate, will be useful additions to the treatment of post-menopausal osteoporosis. Strontium ranelate is a new molecule that both inhibits bon
Publikováno v:
Osteoporosis International. 24:2375-2376
Autor:
P, Garnero, P D, Delmas
Publikováno v:
Journal of musculoskeletalneuronal interactions. 4(1)
In osteoporosis, the main cause for concern is the increase in the risk of fractures. The level of bone mineral density (BMD) measured by various techniques has been shown to be a strong predictor of fracture risk in postmenopausal women. However, ha